These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15690994)

  • 1. Dimension reduction in the linear model for right-censored data: predicting the change of HIV-I RNA levels using clinical and protease gene mutation data.
    Huang J; Harrington D
    Lifetime Data Anal; 2004 Dec; 10(4):425-43. PubMed ID: 15690994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iterative partial least squares with right-censored data analysis: a comparison to other dimension reduction techniques.
    Huang J; Harrington D
    Biometrics; 2005 Mar; 61(1):17-24. PubMed ID: 15737074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors.
    Soret P; Avalos M; Wittkop L; Commenges D; Thiébaut R
    BMC Med Res Methodol; 2018 Dec; 18(1):159. PubMed ID: 30514234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The genetic variability of the protease-encoding region in HIV-1 A isolates and in CRF03_AB recombinants as observed in the CIS territory].
    Sukhanova AL; Kazennova EV; Rudinskiĭ NI; Mikhaĭlovich VM; Griadunov DA; Budilov AV; Bulavkina MA; Weber JN; Pokrovskiĭ VV; Bobkov AF
    Vopr Virusol; 2004; 49(6):4-9. PubMed ID: 15597953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
    Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
    Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BJ: an S-Plus program to fit linear regression models to censored data using the Buckley-James method.
    Stare J; Harrell FE; Heinzl H
    Comput Methods Programs Biomed; 2001 Jan; 64(1):45-52. PubMed ID: 11084232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy.
    Menzo S; Rusconi S; Monachetti A; Colombo MC; Violin M; Bagnarelli P; Varaldo PE; Moroni M; Galli M; Balotta C; Clementi M
    AIDS; 2000 Jun; 14(9):1101-10. PubMed ID: 10894273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India.
    Arora SK; Gupta S; Toor JS; Singla A
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):125-30. PubMed ID: 18240959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals.
    Shafer RW; Warford A; Winters MA; Gonzales MJ
    J Virol Methods; 2000 May; 86(2):143-53. PubMed ID: 10785289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR
    Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.
    Corvasce S; Violin M; Romano L; Razzolini F; Vicenti I; Galli A; Duca P; Caramma I; Balotta C; Zazzi M
    Antivir Ther; 2006; 11(3):329-34. PubMed ID: 16759049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data.
    Flandre P; Alcais A; Descamps D; Morand-Joubert L; Joly V
    J Acquir Immune Defic Syndr; 2004 Mar; 35(3):286-92. PubMed ID: 15076244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.